Guided Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-3.2M | $-2.4M | $-3.5M | $-4.3M | $-2.1M | $-279.0K | $-1.9M | $1.0M |
| Depreciation & Amortization | — | — | — | — | — | $0 | $21.0K | $27.0K |
| Depreciation | $10.0K | $9.0K | $9.0K | $4.0K | $1.0K | $0 | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $377.0K | $120.0K | $1.8M | $1.4M | $228.0K | $309.9K | $8.0K | $44.0K |
| Net Cash from Operating Activities | $-1.1M | $-1.1M | $-1.7M | $-1.5M | $-1.6M | $-1.9M | $-806.0K | $-1.4M |
| Investing Activities | ||||||||
| Capital Expenditures | $2.0K | $0 | $0 | $31.0K | $14.0K | $1.0K | $0 | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-2.0K | $0 | — | $-31.0K | $-14.0K | $-1.0K | $0 | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $745.0K | $916.0K | $24.0K | $3.2M | $2.1M | $1.2M | $1.7M | $1.4M |
| Net Change in Cash | — | $-203.0K | $-1.7M | — | $461.0K | $-717.0K | $899.0K | $-1.0K |
| Free Cash Flow | $-1.1M | $-1.1M | $-1.7M | $-1.5M | $-1.6M | $-1.9M | $-806.0K | — |